The serum levels of ALT above 30 U/L, GGT above 30 U/L, and ALT/AST ratio higher than 1.25 [indicative for NAFLD (55–57)] had 36.9, 48.5, and 40.8% of the participants, respectively. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.